title: Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.
abstract: OBJECTIVE
  In POWER 1 and POWER 2, darunavir (TMC114) with low-dose ritonavir (darunavir/r) demonstrated greater efficacy versus control protease inhibitors (PIs). To examine the efficacy and safety of the selected darunavir/r dose further, additional patients were analyzed.
  
  
  METHODS
  Treatment-experienced HIV-1-infected patients received darunavir/r at a dose of 600/100 mg twice daily plus an optimized background regimen. The primary intent-to-treat analysis was the proportion of patients with an HIV-1 RNA reduction >or=1 log10 at week 24.
  
  
  RESULTS
  Three hundred twenty-seven patients were treated; the baseline mean HIV-1 RNA was 4.6 log10 copies/mL, and the median CD4 count was 115 cells/mm3 (median primary PI mutations = 3, PI resistance-associated mutations = 9). Two hundred forty-six patients reached week 24 by the cutoff date and were included in the efficacy analysis: 65% and 40% achieved HIV-1 RNA reductions of >or=1 log10 and <50 copies/mL, respectively, at week 24. The mean CD4 count increase was 80 cells/mm3. The most common adverse events (AEs) were diarrhea (14%), nasopharyngitis (11%), and nausea (10%). Nine (3%) patients discontinued treatment because of AEs or HIV-1-related events. Six treatment-unrelated deaths (2%) were reported.
  
  
  CONCLUSIONS
  These results corroborate POWER 1 and POWER 2. In this larger set of treatment-experienced patients, darunavir/r at a dose of 600/100 mg twice daily provided substantial virologic and immunologic responses and was generally safe and well tolerated.
authors.affiliation: Assistance Publique--Hôpitaux de Paris, Department of Infectious Diseases, Hôpital St. Louis, Paris, France. jean-michel.molina@sls.aphp.fr
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Molina
authors.forename: Calvin
authors.initials: C
authors.lastname: Cohen
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.forename: Beatriz
authors.initials: B
authors.lastname: Grinsztejn
authors.forename: Artur
authors.initials: A
authors.lastname: Timerman
authors.forename: Rogerio de Jesus
authors.initials: Rde J
authors.lastname: Pedro
authors.forename: Tony
authors.initials: T
authors.lastname: Vangeneugden
authors.forename: Diego
authors.initials: D
authors.lastname: Miralles
authors.forename: Sandra De
authors.initials: SD
authors.lastname: Meyer
authors.forename: Wim
authors.initials: W
authors.lastname: Parys
authors.forename: Eric
authors.initials: E
authors.lastname: Lefebvre
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000069454:Darunavir; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D012367:RNA, Viral / Q000097:blood; D019438:Ritonavir / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D013223:Statistics as Topic; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D013997:Time Factors; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D013449:Sulfonamides; D019438:Ritonavir; D000069454:Darunavir